PROTEINA (KOSDAQ: 468530) is a biotechnology company redefining antibody engineering through single-molecule precision. Its proprietary SPID (Single-molecule Protein-Protein Interaction Detection) platform enables high-throughput, quantitative analysis of complex protein interactions at molecular resolution.

With up to 100-fold higher sensitivity than ELISA, SPID produces reproducible, high-resolution PPI data without purification steps. Its scalable, automation-ready workflow accelerates antibody screening and optimization while capturing molecular-level precision essential for translational research.

Building on this foundation, PROTEINA delivers two integrated platforms. PPI Landscape^® provides high-throughput, multi-parametric antibody optimization—profiling affinity, expression, thermal stability, and pH sensitivity to guide lead selection. PPI PathFinder^® these insights into translational contexts, connecting molecular interaction data to mechanism-of-action confirmation, target engagement, dose response, and patient stratification.

Through these innovations and partnerships, PROTEINA enables global researchers and pharmaceutical organizations to accelerate discovery and apply true molecular precision to therapeutic antibody development.

Boston office:  245 Main Street, CIC Cambridge, Cambridge, MA 02142